Is there a big difference between pazopanib and pazopanib?

Pazopanib and pazopanib are actually different translations of the same drug, so there is no difference in their ingredients, mechanism of action, or therapeutic use. This drug is a targeted drug that belongs to the tyrosine kinase inhibitor class and is mainly used to treat certain types of cancer, including renal cell carcinoma (RCC) and soft tissue sarcoma (STS). Whether it is called "pazopanib" or "pazopanib," they refer to the same drug, with exactly the same ingredients and effects.

The names "pazopanib" and "pazopanib" may be a translation or writing difference. In the international market, the English name of the drug is Pazopanib, while different Chinese names may exist in translations in different regions or languages. Although the names are different, both names refer to the same drug, so their effects, indications, and usage are exactly the same. When purchasing, patients should pay attention to verify the English name and related information of the drug to ensure that they are purchasing the correct drug.

Pazopanib (Pazopanib) works by inhibiting the activity of multiple tyrosine kinases. The main targets include vascular endothelial growth factor receptor ( VEGFR), PDGFR (platelet-derived growth factor receptor) and c-Kit etc. Inhibition of these targets can reduce the blood supply of tumors and prevent the proliferation and spread of tumor cells, thereby effectively controlling tumor growth. The drug is used to treat patients with advanced renal cell carcinoma (RCC) and soft tissue sarcoma (STS). It can effectively prolong the patient's survival and improve their quality of life.

Pazopanib is mainly used to treat cancer types such as renal cell carcinoma and soft tissue sarcoma, especially as an effective targeted therapy in patients whose other treatments have failed or whose disease has progressed. Clinical studies have shown that pazopanib has a significant effect in improving patients' progression-free survival (PFS). In addition, pazopanib can also slow down tumor growth and prolong survival, so it has important clinical value for patients with advanced cancer.

References：https://www.votrient.com/